Brief: Shanghai Junshi Biosciences Says Indications Of Tuoyi & Mindewei Included In National Reimbursement Drug List
13/12/2023 15:57
Dec 13 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* NEW INDICATIONS OF TUOYI AND MINDEWEI INCLUDED IN NEW
EDITION OF
NATIONAL REIMBURSEMENT DRUG LIST
Source text for Eikon: ID:nHKS1RT8YQ
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab